跳至主要内容
临床试验/NCT06287957
NCT06287957招募中不适用

Chitosan Brushes vs Air-Abrasive Devices on Peri-implant Mucositis Treatment: A Randomized Clinical

Istanbul University2 个研究点 分布在 2 个国家目标入组 54 人开始时间: 2024年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
54
试验地点
2
主要终点
Probing Depth

研究概览

简要总结

Bleeding on probing (0,1,2,3), plaque index (+,-) and pocket probing depth will be recorded for each visit. Before the procedure, the patient will be randomly assigned to one of four groups and records will be kept. In the frst visit of the patient, necessary actions will be taken according to the group to which the patient is assigned. The implant periphery of the patients assigned to the chitosan brush group will be debrided with a chitosan brush with circular movements. The implants of the patients assigned to the air abrasive device group will be cleaned in the same way with circular movements. The debrided area of both groups will be washed with sterile serum after the treatment. Patients will be called at the 2nd, 4th and 12th weeks and compared with the records kept.

详细描述

Patients with single implants and single cemented crowns with peri-implant mucositis on their posterior teeth (Premolars and molars) Regular peri-implant mucositis treatment with air-abrasive device and a new method with labrida bioclean brush for cleaning the infection.

Experimental procedures and follow-ups Bleeding on probing (0,1,2,3), plaque index (+,-) and pocket probing depth will be recorded for each visit. Before the procedure, the patient will be randomly assigned to one of four groups and records will be kept. In the frst visit of the patient, necessary actions will be taken according to the group to which the patient is assigned. The implant periphery of the patients assigned to the chitosan brush group will be debrided with a chitosan brush with circular movements. The implants of the patients assigned to the air abrasive device group will be cleaned in the same way with circular movements. The debrided area of both groups will be washed with sterile serum after the treatment. Patients will be called at the 2nd, 4th and 12th weeks and compared with the records kept.

The number of cases to be taken in total, 12 cases, was determined as 48. There will be 54-55 cases with 10% drop out share.

GPOWER PROTOCOL F tests - ANOVA: Repeated measures, between factors Analysis: A priori: Compute required sample size Input: Effect size f = 0.4982302 α err prob = 0.05 Power (1-β err prob) = 0.95 Number of groups = 4 Number of measurements = 4 Corr among rep measures = 0.5 Output: Noncentrality parameter λ = 19.0643199 Critical F = 2.8164658 Numerator df = 3.0000000 Denominator df = 44.0000000 Total sample size = 48 Actual power = 0.9529658 For the results; Data will be analyzed with IBM SPSS V23. Repeated measures analysis of variance will be used to analyze quantitative data. For multiple comparisons, the Bonferroni test will be used. Analysis results will be presented as mean and standard deviation for quantitative data, and frequency and percentage for categorical data. The signifcance level will be taken as p<0.05.

Peri-implant mucositis is the last reversible stage before peri-implantitis. Treatment of the disease at this stage is very important. When treated, bone loss around the implant will be prevented and implant survival will be prolonged.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Presence of peri-implant mucositis around at least one implant,
  • Being over 18 years old,
  • Being psychologically suitable,
  • The teeth adjacent to the relevant implant are natural teeth,
  • Having at least 1 implant in the maxillary or mandibular posterior region (teeth 4, 5, 6 and 7) and a cemented prosthesis that is not connected to other implants or teeth as its superstructure,
  • Probing depth longer than 3 mm and shorter than 5 mm,
  • Evidence of bleeding is required on probing.

排除标准

  • Pregnancy
  • History of chemotherapy and/or radiotherapy received in the past or currently being received,
  • Bone loss around the implant,
  • Presence of an implant in the area adjacent to the relevant implant,
  • Dentures combined with other implants or teeth,
  • Screw-retained prostheses
  • Uncontrolled diabetes

研究组 & 干预措施

ML

Experimental

Patients with mini platform implants to be treated with Labrida Bioclean

干预措施: Labrida BioClean (Procedure)

RL

Experimental

Patients with regular platform implants to be treated with Labrida Bioclean

干预措施: Labrida BioClean (Procedure)

ME

Active Comparator

Patients with mini platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)

干预措施: EMS Handy 3.0 Perio Premium (Procedure)

RE

Active Comparator

Patients with regular platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)

干预措施: EMS Handy 3.0 Perio Premium (Procedure)

结局指标

主要结局

Probing Depth

时间窗: First visit, 2 weeks after the procedure, 4 weeks after the procedure, 8 weeks after the procedure

Probing depth will be recorded for all around the implant on each visit of the patient. One of the inclusion criterias is 3 to 5 mm probing depth around the implant.

次要结局

  • Bleeding on Probing(First visit, 2 weeks after the procedure, 4 weeks after the procedure, 8 weeks after the procedure)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alper Gultekin

Dr.

Istanbul University

研究点 (2)

Loading locations...

相似试验